← Leaderboards
Ken A Witt
University Of Arizona
$3,969,769
Attributed
$3,969,769
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $770.4K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,969,769 · 5
By mechanism
R01$2,831,907 · 1
R21$718,047 · 2
R16$286,147 · 1
F32$133,668 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseEvaluationPharmaceutical PreparationsDoseChronicMouse ModelMemoryPublic Health RelevanceBaseAgonistPermeabilityObject RecognitionNeurodegenerative DisordersPathologyIn VivoLearningAffinityAmyloid Beta-ProteinHippocampus (Brain)Impaired CognitionAffectDrug Discovery
Grant awards (15)
Dopamine and Sigma Receptor Mixed Modulators for the Treatment of Alzheimer's Disease$144,500
R16 · FY2025 · NS · contact PI
Dopamine and Sigma Receptor Mixed Modulators for the Treatment of Alzheimer's Disease$141,647
R16 · FY2024 · NS · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$502,232
R01 · FY2019 · AG · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$543,910
R01 · FY2018 · AG · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$544,840
R01 · FY2017 · AG · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$181,248
R01 · FY2017 · AG · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$506,067
R01 · FY2016 · AG · contact PI
Dietary impact on blood-brain barrier tight junctions$180,625
R21 · FY2016 · NS · contact PI
Lead optimization of somatostatin-based therapeutic for Alzheimer's Disease$553,610
R01 · FY2015 · AG · contact PI
Dietary impact on blood-brain barrier tight junctions$216,750
R21 · FY2015 · NS · contact PI
Somatostatin Agonist Treatment for Cognitive Aging and Dementia$146,422
R21 · FY2010 · AG · contact PI
Somatostatin Agonist Treatment for Cognitive Aging and Dementia$174,250
R21 · FY2009 · AG · contact PI
Blood-brain barrier changes via hypoxia/re-oxygenation$48,928
F32 · FY2004 · NS
Blood-brain barrier changes via hypoxia/re-oxygenation$46,420
F32 · FY2003 · NS
Blood-brain barrier changes via hypoxia/re-oxygenation$38,320
F32 · FY2002 · NS